Antiviral prophylaxis during pandemic influenza may increase drug resistance

BMC Infectious Diseases

Volumn 9, Issue , 2009, Pages

  Eichner, Martin ^a   Schwehm, Markus ^b   Duerr, Hans Peter ^a   Witschi, Mark ^c   Koch, Daniel ^c   Brockmann, Stefan O ^d   Vidondo, Beatriz ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b EXPLOSYS GMBH   (Germany)

^c FEDERAL OFFICE OF PUBLIC HEALTH   (Switzerland)

^d Baden Wurttemberg State Health Office   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; SIALIDASE INHIBITOR; ENZYME INHIBITOR; SIALIDASE;

ADOLESCENT; ADULT; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CHILD; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG EXPOSURE; HOSPITALIZATION; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MORTALITY; PANDEMIC; POPULATION RESEARCH; PREVALENCE; VIRUS STRAIN; VIRUS TRANSMISSION; ANTIVIRAL RESISTANCE; BIOLOGICAL MODEL; COMPUTER SIMULATION; DRUG ANTAGONISM; DRUG EFFECT; EPIDEMIC; ORTHOMYXOVIRUS; UNCERTAINTY; VIROLOGY;

ANTIVIRAL AGENTS; COMPUTER SIMULATION; DISEASE OUTBREAKS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HUMANS; INFLUENZA, HUMAN; MODELS, BIOLOGICAL; NEURAMINIDASE; ORTHOMYXOVIRIDAE; PREVALENCE; UNCERTAINTY;

EID: 62449238119     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-9-4     Document Type: Article

References (23)

1. Ferguson NM Cummings DA Cauchemez S Fraser C Riley S Meeyai A Iamsirithaworn S Burke DS Strategies for containing an emerging influenza pandemic in Southeast Asia Nature 2005, 437(7056):209-214. 10.1038/nature04017 16079797
2. Longini IM Jr Halloran ME Nizam A Yang Y Containing pandemic influenza with antiviral agents Am J Epidemiol 2004, 159(7):623-633. 10.1093/aje/ kwh092 15033640
3. Longini IM Jr Nizam A Xu S Ungchusak K Hanshaoworakul W Cummings DA Halloran ME Containing pandemic influenza at the source Science 2005, 309(5737):1083-1087. 10.1126/science.1115717 16079251
4. Alexander ME Bowman CS Feng Z Gardam M Moghadas SM Rost G Wu J Yan P Emergence of drug resistance: Implications for antiviral control of pandemic influenza Proc R Soc Lond B Biol Sci 2007, 274(1619):1675-1684. 10.1098/rspb.2007.0422
5. Lipsitch M Cohen T Murray M Levin BR Antiviral Resistance and the Control of Pandemic Influenza PLoS Med 2007, 4(1):e15. 1779817 17253900 10.1371/journal.pmed.0040015
6. Regoes RR Bonhoeffer S Emergence of drug-resistant influenza virus: population dynamical considerations Science 2006, 312(5772):389-391. 10.1126/science.1122947 16627735
7. Stilianakis NI Perelson AS Hayden FG Emergence of drug resistance during an influenza epidemic: Insights from a mathematical model J Infect Dis 1998, 177(4):863-873. 9534957
8. Blower SM Gershengorn HB Grant RM A tale of two futures: HIV and antiretroviral therapy in San Francisco Science 2000, 287(5453):650-654. 10.1126/science.287.5453.650 10649998
9. Blower SM Porco TC Darby G Predicting and preventing the emergence of antiviral drug resistance in HSV-2 Nat Med 1998, 4(6):673-678. 10.1038/ nm0698-673 9623975
10. Yen HL Ilyushina NA Salomon R Hoffmann E Webster RG Govorkova EA Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo J Virol 2007, 81(22):12418-12426. 2169015 17855542 10.1128/JVI.01067-07
11. Lackenby A Hungnes O Dudman SG Meijer A Paget WJ Hay AJ Zambon MC Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe Euro surveill 2008, 13:5. 18445375
12. Eichner M Schwehm M Duerr HP Brockmann SO The influenza pandemic preparedness planning tool InfluSim BMC Infect Dis 2007, 7:17. 1832202 17355639 10.1186/1471-2334-7-17
13. InfluSim http://www.influsim.info
14. Chowell G Nishiura H Bettencourt LM Comparative estimation of the reproduction number for pandemic influenza from daily case notification data J R Soc Interface 2007, 4(12):155-166. 2358966 17254982 10.1098/ rsif.2006.0161
15. Kaiser L Wat C Mills T Mahoney P Ward P Hayden F Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations Arch Intern Med 2003, 163(14):1667-1672. 10.1001/ archinte.163.14.1667 12885681
16. Aoki FY Boivin G Roberts N Influenza virus susceptibility and resistance to oseltamivir Antivir Ther 2007, 12(4 Pt B):603-616. 17944268
17. Tamiflu. Arzneimittel-Kompendium der Schweiz http://www.kompendium.ch
18. Handel A Regoes RR Antia R The role of compensatory mutations in the emergence of drug resistance PLoS Comput Biol 2006, 2(10):e137. 1599768 17040124 10.1371/journal.pcbi.0020137
19. Updated review of influenza antiviral medicinal products for potential use during pandemic by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) http://www.emea.europa.eu/htms/human/pandemicinfluenza/antivirals.htm
20. Moghadas SM Bowman CS Rost G Wu J Population-wide emergence of antiviral resistance during pandemic influenza PLoS ONE 2008, 3(3):e1839. 2266801 18350174 10.1371/journal.pone.0001839
21. Moghadas SM Management of drug resistance in the population: Influenza as a case study Proc R Soc B 2008. 18270154
22. Duerr HP Brockmann SO Piechotowski I Schwehm M Eichner M Influenza pandemic intervention planning using InfluSim: Pharmaceutical and non-pharmaceutical interventions BMC Infect Dis 2007, 7(1):76. 1939851 17629919 10.1186/1471-2334-7-76
23. McCaw JM Wood JG McCaw CT McVernon J Impact of emerging antiviral drug resistance on influenza containment and spread: Influence of subclinical infection and strategic use of a stockpile containing one or two drugs PLoS ONE 2008, 3(6):e2362. 2390853 18523549 10.1371/journal.pone.0002362